These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
94 related items for PubMed ID: 24968481
21. Insulin detemir (levemir), a new long-acting insulin. Med Lett Drugs Ther; 2006 Jul 03; 48(1238):54-5. PubMed ID: 16841022 [Abstract] [Full Text] [Related]
22. At last, a weight neutral insulin? Fritsche A, Häring H. Int J Obes Relat Metab Disord; 2004 Sep 03; 28 Suppl 2():S41-6. PubMed ID: 15306837 [Abstract] [Full Text] [Related]
23. The gain game. Gebel E. Diabetes Forecast; 2012 Oct 03; 65(10):28-9. PubMed ID: 23038947 [No Abstract] [Full Text] [Related]
24. Insulin and oral hypoglycemic agents should not be used in combination in the treatment of type 2 diabetes. Westphal SA, Palumbo PJ. Arch Intern Med; 2012 Oct 03; 163(15):1783-5; discussion 1785. PubMed ID: 12912711 [No Abstract] [Full Text] [Related]
25. Exorcising the specter of nighttime hypoglycemia. Scheiner G. Diabetes Self Manag; 2012 Oct 03; 29(1):16, 18-20. PubMed ID: 22482132 [No Abstract] [Full Text] [Related]
26. [Syndrome of chronic overdose of insulin and hypoglycemic sulfanilamide drugs]. Arzumetova DS, Saburenko MB, Shagazatova BKh, Zabikhodzhaeva GZ. Klin Med (Mosk); 1989 Apr 03; 67(4):99-101. PubMed ID: 2666739 [Abstract] [Full Text] [Related]
27. The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study. Fischer JS, McLaughlin T, Loza L, Beauchamp R, Schwartz S, Kipnes M. Curr Med Res Opin; 2004 Nov 03; 20(11):1703-10. PubMed ID: 15537471 [Abstract] [Full Text] [Related]
28. Health economic evaluation of insulin glargine vs NPH insulin in intensified conventional therapy for type 1 diabetes in Germany. Pfohl M, Schädlich PK, Dippel FW, Koltermann KC. J Med Econ; 2012 Nov 03; 15 Suppl 2():14-27. PubMed ID: 22812690 [Abstract] [Full Text] [Related]
30. The safety profile of exogenous insulin in people with type 2 diabetes: justification for concern. Currie CJ, Johnson JA. Diabetes Obes Metab; 2012 Jan 03; 14(1):1-4. PubMed ID: 21736688 [Abstract] [Full Text] [Related]
32. [Multiple insulin injections therapy as an intensive insulin therapy]. Kishikawa H, Wake N, Shichiri M. Nihon Rinsho; 1997 Nov 03; 55 Suppl():249-54. PubMed ID: 9434476 [No Abstract] [Full Text] [Related]
33. Insulin detemir: a new basal insulin analogue. Soran H, Younis N. Diabetes Obes Metab; 2006 Jan 03; 8(1):26-30. PubMed ID: 16367879 [Abstract] [Full Text] [Related]
34. Hypoglycemia in patients with type 2 diabetes using concomitant exenatide BID and long-acting insulin therapy. Pawaskar MD, Blickensderfer AL, Hoogwerf BJ, Quimbo R, Wade R. J Med Econ; 2011 Jan 03; 14(6):705-8. PubMed ID: 21892855 [Abstract] [Full Text] [Related]
35. Accuracy of self-mixed small quantities of insulin. Bell DS. Endocr Pract; 2012 Jan 03; 18(4):616; author reply 616-7. PubMed ID: 22849878 [No Abstract] [Full Text] [Related]
36. [Are the most recent basal insulins really the most innovative?]. Laudo Pardos C, Puigdevall Gallego V. Med Clin (Barc); 2016 Oct 07; 147(7):297-9. PubMed ID: 27369693 [No Abstract] [Full Text] [Related]
37. THE USE OF INSULIN IN UNSTABLE DIABETES MELLITUS. MARLER E, BRESSLER R, STYRON C. South Med J; 1964 Dec 07; 57():1447-51. PubMed ID: 14226910 [No Abstract] [Full Text] [Related]
38. Lessons on developing a better basal insulin. Ahmann A. Diabetes Technol Ther; 2004 Oct 07; 6(5):596-600. PubMed ID: 15628813 [No Abstract] [Full Text] [Related]